<DOC>
	<DOCNO>NCT01119677</DOCNO>
	<brief_summary>This randomize , 3-arm , dose-blinded , parallel-group study . Subjects randomize one 3 treatment titration regime ( slow titration 6 week , fast titration 3 week , titration ) .</brief_summary>
	<brief_title>A Study AvonexÂ® Determine Effects Dose Titration Incidence Flu Like Symptoms Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>Must healthy male female age 18 55 year old time inform consent . Must Body Mass Index 19 30 kg/m2 , minimum body weight 50.0 kg Screening . Female subject childbearing potential must practice effective contraception study willing able continue contraception 30 day last dose study treatment . Known history positive test result human immunodeficiency virus ( HIV ) , hepatitis C virus ( test hepatitis C virus antibody [ HCV Ab ] ) hepatitis B virus ( test hepatitis B surface antigen [ HBsAg ] hepatitis B core antibody [ HBcAb ] ) Known history chronic fatigue syndrome fibromyalgia Within one month , flulike illness ( e.g. , gastroenteritis , upper respiratory infection , common cold ) History severe allergic reaction drug anaphylactic reaction Known allergy Avonex component Serious infection ( e.g. , pneumonia , septicemia ) within 3 month prior Screening active bacterial viral infection History alcohol substance abuse ( define Investigator ) Female subject pregnant currently breastfeed Any previous treatment interferon product.10 . Vaccinations within 2 week 5 halflives , whichever longer , prior Day 1 Blood donation within 30 day prior Screening Use tobacco product 5 time within 30 day prior Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>